Technology Commercialization and Partnerships | BSA 09-12 & 13-11: Radiolabeled Vorozole for Breast Cancer Monitoring

Print Friendly

Category: biotechnology & health

BSA 09-12 & 13-11: Radiolabeled Vorozole for Breast Cancer Monitoring

BNL Reference Number: BSA 09-12

Patent Status: Application Number 20100209344 was published on August 19, 2010

Summary

In these PET scans, taken from the front to the back of the head, color indicates the level of vorozole, a molecule that binds to the enzyme responsible for estrogen production in the brain (following the rainbow spectrum, red is the highest level, blue the lowest). These illustrate the regions found to have the highest levels of estrogen production (from left the thalamus, amygdala, and medulla oblongata's inferior olive), a pattern that was consistent across all six subjects and may be unique to humans.

Diagnosis, treatment and monitoring of estrogen-sensitive breast cancers will be simplified by the development of [¹¹C]vorozole as a positron emission tomography (PET) tracer. This invention provides highly purified labeled vorozole for cancer diagnosis, treatment and treatment monitoring.

Description

Methods for the production of highly purified [¹¹C] labeled vorozole are provided. The highly pure radio-labeled compound is separated from a previously unrecognized contaminating isomer, resulting in a compound offering excellent specificity.